Answers are grounded in this paper and cite their sources.
Explores folate receptor alpha's role in platinum sensitivity in high-grade serous ovarian cancer, indicating potential for better patient selection.
Folate receptor alpha (FRα)-targeted antibody-drug conjugates are approved in platinum-resistant high-grade serous ovarian cancer (HGSOC) and are being explored in multiple clinical settings. The full clinical significance of FRα expression remains unclear: whether it varies by sample timing or type, overlaps with homologous recombination deficiency (HRD), or influences platinum sensitivity, with implications for biomarker-driven patient selection.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: